MCS
DMAA

Mercuria Capital Strategies’s Drugs Made In America Acquisition Corp DMAA Stock Holding History

Mercuria Capital Strategies’s Portfolio DMAA Stock Details DMAA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-750,000
Closed -$7.51M – 41
2025
Q4 		$7.51M Buy
+750,000
New +$7.74M 4.27% 6

Other funds holding DMAA

KIM
Karpus Investment Management Pittsford, New York $3.21B AUM 6.83% 1-Year Est. Return
FTCM
First Trust Capital Management Chicago, Illinois $1.9B AUM 58.28% 1-Year Est. Return
MSU
Mizuho Securities USA New York $6.2B AUM 35.46% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
WCMNY
Westchester Capital Management (New York) Valhalla, New York $2.21B AUM 26.02% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.02% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.21% 1-Year Est. Return
AC
Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.91% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Mercuria Capital Strategies's DMAA Position: Q1 2026 in Review

Mercuria Capital Strategies sold out of Drugs Made In America Acquisition Corp (DMAA) in Q1 2026, closing a stake of 750,000 shares — an estimated $7.51M sold.

Mercuria Capital Strategies first reported a position in DMAA in Q4 2025 and held it in 1 quarter. The position peaked at $7.51M in Q4 2025. 39 funds tracked by Wall St. Rank hold DMAA as of Q1 2026.

  • Mercuria Capital Strategies reported no remaining Drugs Made In America Acquisition Corp position as of Q1 2026 after selling out during the quarter.
  • Mercuria Capital Strategies sold 750,000 Drugs Made In America Acquisition Corp shares in Q1 2026, an estimated $7.51M.
  • Mercuria Capital Strategies first reported a position in Drugs Made In America Acquisition Corp in Q4 2025 and held it in 1 quarter.
  • Mercuria Capital Strategies's Drugs Made In America Acquisition Corp position peaked at $7.51M in Q4 2025.
  • 39 funds tracked by Wall St. Rank held Drugs Made In America Acquisition Corp as of Q1 2026.

Based on Mercuria Capital Strategies's 13F filing for Q1 2026, filed 6 May 2026.